There have been rare cases of hypothyroidism in patients, particularly term and preterm infants, exposed to ICM reported internationally. No Canadian cases of hypothyroidism related to ICM exposure have been identified to date. Products affected Product Medicinal Ingredient Company Gastrografin - LIQ ORL Diatrizoate Meglumine and Diatrizoate Sodium Solution Bracco Imaging Canada Sinografin LIQ IU Diatrizoate Meglumine and Iodipamide Meglumine Injection Bracco Imaging Canada Isovue 200, 300, 370 Injection / Isovue Multipack -300, 370 Iopamidol Injection Bracco Imaging Canada Cholografin Meglumine INJ.-LIQ IV Meglumine Iodipamide Injection Bracco Imaging Canada Visipaque 270, 320 Iodixanol Injection GE Healthcare Canada Inc. Omnipaque 180, 240, 300,350 Iohexol Injection GE Healthcare Canada Inc. Ultravist 240, 300, 370 Iopromide Injection Bayer Inc. Conray 30, 43, 60 Iothalamate Meglumine Injection Liebel-Flarsheim Canada Inc. Cysto-Conray II Iothalamate Meglumine Injection Liebel-Flarsheim Canada Inc. Optiray 240, 300, 320, 350 Ioversol Injection Liebel-Flarsheim Canada Inc. Telebrix 38 Oral Meglumine Ioxitalamate and Sodium Ioxitalamate Oral Solution Liebel-Flarsheim Canada Inc.
RecallTracker